Normoxia Sverige AB

Active
559380-8461Limited company (AB)Registered 2022ARVIKA

Key figures

0 kr−100,0%
Revenue 2025/26
0100 k200 k300 k400 k2022/232023/242024/252025/26

Key figures

2025/26

Summary: Normoxia Sverige AB

What kind of company is it?

Normoxia Sverige AB (org. no. 559380-8461) is a limited company (AB). The company was registered in 2022 and has existed for 4 years. Registered seat: Arvika. Industry according to Statistics Sweden: research and experimental development on biotechnology (SNI 72101).

How is the company doing financially?

The company had no net sales in financial year 2026. Financial year 2026 ended with a loss of 15 270 kr. The company was profitable in 3 of the 4 reported financial years. At the end of financial year 2026, total assets were 50 053 kr and equity 38 724 kr (equity ratio 77,4 %).

Where does the data come from and how up to date is it?

Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by one person. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.

Dividend

from the annual report
2024/25

Proposed dividend 200 000 kr.

History
2024/25200 000 kr
2023/24170 000 kr
Summary of annual reports2023–2026
2022/232023/242024/252025/26
Sales revenue129 000156 000312 0000
Profit for the reporting year95 54888 970214 476−15 270
Retained earnings of previous periods————
Total assets128 541243 738302 09150 053
Total liabilities7 99334 22048 09811 329
Total equity120 548209 518253 99338 724
Employees————
Proposed dividend—170 000200 000—

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.